Analysts give Gossamer Bio, Inc. (NASDAQ:GOSS) a “Moderate Buy” recommendation.
According to Bloomberg, the eleven research companies currently monitoring NASDAQ: Gossamer Bio, Inc.’s GOSS shares gave the stock an average rating of “Moderate Buy,” indicating that investors should consider buying Gossamer Bio, Inc.’s stock. the society. Additionally, the stock received ten recommendations from equity research experts to buy it, while there was only one recommendation to hold its current holdings in the stock.
Several different research companies have given their opinion on GOSS. JPMorgan Chase & Co. began their coverage of Gossamer Bio on September 21, when they released a report on the company. This report marked the beginning of their coverage. They gave the stock a “neutral” rating and concluded that the price of the stock should be $17.00. In a research report released on Thursday, July 14, Raymond James raised his target price on Gossamer Bio from $10.00 to $14.00 in a research report. On the same day, they also rated the company’s stock as an “outperformer,” indicating that they believe its price will rise. Wedbush originally covered Gossamer Bio in a report published Sept. 19 and marked the start of company coverage of the business. They gave the company an “outperform” rating and determined that a price target of $24.00 was appropriate. In a research report published August 17, Barclays upgraded Gossamer Bio from an “underweight” to an “overweight” rating and increased its target price on the stock from $12.00 to $18.00. $. In a report released Thursday, July 14, HC Wainwright reaffirmed its “buy” rating on Gossamer Bio shares and positioned its price target for the company’s shares at $20.00. The report focused on the company’s quarterly results.
On Friday, July 15, Bryan Giraudo, the company’s chief financial officer, purchased 13,869 shares of the company. This information is relevant to the topic of this discussion. The total amount spent to purchase the shares was $99,995.49, or an average price of $7.21 per share. The price was determined by multiplying the total amount spent by the number of shares purchased. The CFO currently owns 20,990 shares, with a total value of $151,337.90. If you follow this link, you will be redirected to a document filed with the Securities and Exchange Commission (SEC). The document contains a detailed explanation of the transaction reported to the SEC. Gossamer Bio CFO Bryan Giraudo purchased 13,869 shares on Friday, July 15, according to other recent news related to Gossamer Bio. The total cost of acquiring the shares was $99,995.49, which equates to an average price of $7.21 per share throughout the transaction. The CFO currently owns 20,990 shares, which have a collective value of $151,337.90 and are owned by the CFO. If you follow this link, you will be redirected to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed. You can just ignore this link if you don’t want to follow it. Additionally, on July 15, insider Laura Carter purchased 6,934 shares of the company. This transaction has taken place. When the stock was purchased, a total of $49,994.14 was spent, which equals $7.21 per share divided by the number of shares purchased. After the acquisition, the company insider now directly owns 87,168 shares. The total value of these shares is $628,481.28, which gives the insider a substantial financial stake in the company. You should visit this location if you are looking for disclosure related to this transaction. Over the past three months, company insiders have purchased a total of 159,499 shares for $1,149,988. With the number of shares currently outstanding, insiders of the company own 8.30% of the company.
The past few months have seen several institutional investors adjust the way they hold GOSS. In the first three months of 2018, Point72 Hong Kong Ltd spent around $33,000 to buy a new stake in Gossamer Bio. Additionally, in the first three months of this year, Amalgamated Bank initiated a new position in Gossamer Bio by investing approximately $65,000. During the second quarter of the fiscal year, Gossamer Bio made a new investment in Gossamer Bio by purchasing approximately $75,000 worth of company stock. Additionally, in the first three months of the year, the Teacher Retirement System of Texas acquired Gossamer Bio for approximately $89,000. Last but not least, during the second quarter, Corton Capital Inc. made a brand new investment in Gossamer Bio which was estimated to be worth approximately $91,000. Institutional investors and hedge funds collectively own 67.57% of the total number of shares outstanding in the company.
When the NASDAQ GOSS market opened on Friday, the opening price was $12.18. Over the past year, the price of Gossamer Bio has ranged from a record low of $5.64 to an all-time high of $15.19. A debt ratio of 7.44, a current ratio of 5.24 and a quick ratio identical to the current ratio are some of the financial ratios that have been calculated. Additionally, the company’s moving average over the past 50 days is $13.31, while the moving average over the past 200 days is $10.08. The company’s market cap is currently $1.14 billion, its price-to-earnings ratio is currently 4.01, and its beta value is currently 0.96.
Gossamer Bio (NASDAQ:GOSS) announced the results of its latest quarterly earnings report on Tuesday, August 9. The company said its earnings per share (EPS) for the quarter was $0.74, $0.07 lower than the estimate that market analysts had collectively offered, which was $0.67. $. As a result, sell-side analysts believe Gossamer Bio will lose $2.77 per share for the current fiscal year.
Gossamer Bio, Inc. is a United States-based clinical-stage biopharmaceutical company focused on the discovery of new drugs for diseases related to inflammation, oncology and immunology, as well as the acquisition of these drugs, the development of those drugs, and the sale of those drugs to customers. In addition, the Company is also focused on the development of these drugs and the sale of these drugs to customers. The company is working on three different small molecule therapies: GB002, an inhaled small molecule inhibiting colony stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor (PDGFR), and c-KIT; GB004, a small molecule targeting the oral gut; and GB5121, an oral irreversible covalent small molecule inhibitor of Bruton’s disease. These are being studied as possible ways to treat pulmonary arterial hypertension (PAH).